These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

574 related items for PubMed ID: 26780533

  • 1. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence.
    Dalén J, Svedbom A, Black CM, Lyu R, Ding Q, Sajjan S, Sazonov V, Kachroo S.
    Rheumatol Int; 2016 Jul; 36(7):987-95. PubMed ID: 26780533
    [Abstract] [Full Text] [Related]

  • 2. Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors.
    Dalén J, Svedbom A, Black CM, Kachroo S.
    Rheumatol Int; 2017 Dec; 37(12):2049-2058. PubMed ID: 28975392
    [Abstract] [Full Text] [Related]

  • 3. Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study.
    Dalén J, Luttropp K, Svedbom A, Black CM, Kachroo S.
    Adv Ther; 2020 Sep; 37(9):3746-3760. PubMed ID: 32647910
    [Abstract] [Full Text] [Related]

  • 4. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG, Sinigaglia L, Becciolini A, Grosso V, Gorla R, Bazzani C, Atzeni F, Sarzi Puttini PC, Fusaro E, Pellerito R, Caporali R.
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [Abstract] [Full Text] [Related]

  • 5. Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database.
    Bhoi P, Bessette L, Bell MJ, Tkaczyk C, Nantel F, Maslova K.
    BMJ Open; 2017 Sep 18; 7(9):e015872. PubMed ID: 28928177
    [Abstract] [Full Text] [Related]

  • 6. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B, Chen CI, Proudfoot C, Shinde S, Kuznik A, Wei W.
    Adv Ther; 2017 Nov 18; 34(11):2422-2435. PubMed ID: 29039054
    [Abstract] [Full Text] [Related]

  • 7. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C, Tzioufas A, Goules A, Kourlaba G, Theodoratou T, Christou P, Maniadakis N.
    Rheumatol Int; 2017 Sep 18; 37(9):1441-1452. PubMed ID: 28523420
    [Abstract] [Full Text] [Related]

  • 8. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N, Lee YC, Shah N, Harrison DJ.
    Clin Ther; 2014 Aug 01; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [Abstract] [Full Text] [Related]

  • 9. Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors.
    Tymms K, Littlejohn G, Griffiths H, de Jager J, Bird P, Joshua F, Nash P, Handel M, McManus H, Butcher BE, Youssef P.
    Clin Rheumatol; 2018 Jun 01; 37(6):1617-1623. PubMed ID: 29667098
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP, Incerti D, Mutebi A, Peneva D, MacEwan JP, Stolshek B, Kaur P, Gharaibeh M, Strand V.
    J Med Econ; 2017 Jul 01; 20(7):703-714. PubMed ID: 28294642
    [Abstract] [Full Text] [Related]

  • 11. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J, Alerany-Pardo C, Borrás-Blasco J, Broto-Sumalla A, Burgos-SanJosé A, Climent-Bolta C, Escudero-Vilaplana V, Fernández-Fuente MA, Ferrit-Martin M, Gómez-Germá P, Martínez-Sesmero JM, Mayorga-Pérez J, Menchén-Viso B, Merino-Alonso J, Polache-Vengud J, Sánchez-Guerrero A.
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jul 01; 15(5):851-8. PubMed ID: 25972066
    [Abstract] [Full Text] [Related]

  • 12. Impact of Non-Persistence on Healthcare Resource Utilization and Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study.
    Carballo N, Garcia-Alzórriz E, Ferrández O, Navarrete-Rouco ME, Durán-Jordà X, Pérez-García C, Monfort J, Cots F, Grau S.
    Front Pharmacol; 2021 Jul 01; 12():752879. PubMed ID: 34912219
    [Abstract] [Full Text] [Related]

  • 13. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.
    J Manag Care Pharm; 2013 Oct 01; 19(8):621-30. PubMed ID: 24074008
    [Abstract] [Full Text] [Related]

  • 14. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
    Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, Meroni PL.
    Arthritis Care Res (Hoboken); 2016 Apr 01; 68(4):432-9. PubMed ID: 26556048
    [Abstract] [Full Text] [Related]

  • 15. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A, Barner JC, Lawson KA, Novak S, Rascati KL, Richards KM, Harrison DJ.
    J Manag Care Spec Pharm; 2014 Jul 01; 20(7):657-67. PubMed ID: 24967519
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.
    Yang M, Galebach PJ, Signorovitch JE, Garg V.
    Clin Exp Rheumatol; 2017 Jul 01; 35(5):791-798. PubMed ID: 28339358
    [Abstract] [Full Text] [Related]

  • 17. Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study.
    Dalén J, Chitkara A, Svedbom A, Olofsson T, Puenpatom A, Black CM, Qureshi ZP.
    Adv Ther; 2022 Jun 01; 39(6):2468-2486. PubMed ID: 34751912
    [Abstract] [Full Text] [Related]

  • 18. Cost of dose escalation in people with rheumatoid arthritis treated with tumour necrosis factor inhibitors across Europe.
    Holden SE, Currie CJ, Lennon M, Reynolds AV, Moots RJ.
    Clin Exp Rheumatol; 2016 Jun 01; 34(4):679-84. PubMed ID: 27191345
    [Abstract] [Full Text] [Related]

  • 19. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
    Chastek B, Becker LK, Chen CI, Mahajan P, Curtis JR.
    J Med Econ; 2017 May 01; 20(5):464-473. PubMed ID: 28010149
    [Abstract] [Full Text] [Related]

  • 20. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M, Joseph GJ, Princic N, Harrison DJ.
    J Med Econ; 2013 Sep 01; 16(9):1120-8. PubMed ID: 23808901
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.